戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  of immunocompromising conditions or central nervous system disease.
2 eactivated by inflammation and cause central nervous system disease.
3 -VA1 strain has been associated with central nervous system disease.
4 or the creation of viable therapies to treat nervous system disease.
5  has also been associated with fatal central nervous system disease.
6 tes JHM.WU and JHM.SD promote severe central nervous system disease.
7 by Escherichia coli K1, is a serious central nervous system disease.
8 of symptoms or signs consistent with central nervous system disease.
9  may shed new light on mechanisms underlying nervous system disease.
10 d therapeutic approaches to this challenging nervous system disease.
11 n that causes devastating ocular and central nervous system disease.
12 ly relapsed with disseminated and/or central nervous system disease.
13 at points to new strategies for treatment of nervous system disease.
14  of either copper or iron results in central nervous system disease.
15 proteins, which leads to progressive central nervous system disease.
16  requirement for X4 viruses to cause central nervous system disease.
17 r for the development of HIV-induced central nervous system disease.
18 proaches to promote functional recovery from nervous system diseases.
19 vesicle proteins have been linked to central nervous system diseases.
20 on signaling pathway and was associated with nervous system diseases.
21 ology that enables drug delivery for central nervous system diseases.
22 probes, with a focus on their use in central nervous system diseases.
23  and parasitic diseases, and 82 (18.5%) from nervous system diseases.
24 e, eosinophilic esophagitis, ophthalmic, and nervous system diseases.
25 ascular, renal, cerebrovascular, and central nervous system diseases.
26 iseases, and 57.11 (95% CI, 45.23-72.11) for nervous system diseases.
27 e resource for post-GWAS research on central nervous system diseases.
28 prioritize additional genes for five central nervous system diseases.
29 of neuroinflammation in a variety of central nervous system diseases.
30 ed for the treatment of a variety of central nervous system diseases.
31 itors in clinical trials for various central nervous system diseases.
32 ty's interests in ameliorating the impact of nervous system diseases.
33 ts in the brain for the treatment of central nervous system diseases.
34 for patients with cardiovascular and central nervous system diseases.
35  have been implicated in a number of central nervous system diseases.
36 ring neuronal development and upregulated in nervous system diseases.
37  translational studies in stroke and central nervous system diseases.
38 r HHV-6 in the pathogenesis of these central nervous system diseases.
39 atins as a treatment of inflammatory central nervous system diseases.
40 nflammatory conditions, particularly central nervous system diseases.
41 on associated with several different central nervous system diseases.
42 esis of poorly understood idiopathic central nervous system diseases.
43 nantiepileptic drug (13%), and acute central nervous system disease (12%).
44  50.5 +/- 13.8 yrs, p < .001), acute central nervous system disease (21% vs. 4%, p = .001), mechanica
45 ension; 3) extraocular extension; 4) central nervous system disease; 5) conventional MRI characterist
46 caques can cause fatal demyelinating central nervous system disease analogous to progressive multifoc
47       The hPSD is an important structure for nervous system disease and behavior.
48  future perspectives for modeling of central nervous system disease and brain development in vitro.
49  glia to perform their critical responses to nervous system disease and injury, including active tiss
50 luding corneal opacities, multifocal central nervous system disease and progressively worsening clini
51 type 2 and 3) or absence (type 1) of central nervous system disease and severity of clinical manifest
52 he brains of some AIDS patients with central nervous system disease and suggest that R5 variants with
53 fining criteria of antibody-mediated central nervous system disease and the extent to which the psych
54 though Alzheimer's disease (AD) is a central nervous system disease and type 2 diabetes MELLITUS (T2D
55  1 (GLT8D1) has been associated with central nervous system diseases and cancer.
56 nd that mimic certain aspects of the central nervous system diseases and immunosuppression that can o
57 tion of the potential of STS-E412 in central nervous system diseases and organ protection is warrante
58  encephalitis and other complement-dependent nervous system diseases and thus underscore the need for
59 ears, immunocompromise, a history of central nervous system disease, and a history of seizure within
60 to generate a current picture of the central nervous system disease, and emphasize potential aspects
61 nitial white blood cell (WBC) count, central nervous system disease, and risk group.
62 lities in addictive disorders, other central nervous system diseases, and Alzheimer's disease.
63  including malignancy, pulmonary and central nervous system diseases, and medications.
64 ected with human metabolic diseases, central nervous system diseases, and neoplasms.
65 ions, medications, and rare cases of central nervous system disease are much less common.
66  for the treatment of central and peripheral nervous system diseases associated with excess glutamate
67 lso underlie acquired peripheral and central nervous system diseases associated with small-cell lung
68            Beyond its effects in the central nervous system, disease-associated mutant HTT causes abe
69     We propose a PM architecture for central nervous system diseases built on four converging pillars
70 by the lack of objective measures of central nervous system disease burden.
71  a progressive and severe human degenerative nervous system disease caused by a primary astroglial ab
72 tial strategies to prevent and treat central nervous system disease caused by RVFV and discuss remain
73 drome epidemics, cases of CNS and peripheral nervous system disease caused by SARS-CoV-2 might be exp
74 behavioral and neurodevelopmental disorders; nervous system diseases; circulatory diseases; respirato
75 system itself may have beneficial effects in nervous system diseases considered neurodegenerative.
76                                      Central nervous system disease continues to be difficult to diag
77 y modified cells in animal models of central nervous system disease encourage the continued developme
78                                      Central nervous system disease frequently results in high case-f
79 euroborreliosis but also of what constitutes nervous system disease generally.
80                           Concurrent central nervous system disease has been correlated to a poor vis
81      Adeno-associated viral vectors to treat nervous system disease have been evaluated in the large
82 nce and the genetic and mechanistic basis of nervous system disease have demonstrated that neurologic
83  were indexed with the following MeSH terms: nervous system diseases, immune system diseases, endocri
84 of toxoplasmosis, a leading cause of central nervous system disease in AIDS.
85                      Therefore, we evaluated nervous system disease in feline MLII.
86     Identification of biomarkers for central nervous system disease in MPS patients would facilitate
87 mproved understanding of the pathogenesis of nervous system disease in these infections; more effecti
88 ors between those three inflammatory central nervous system diseases in adults and children to suppor
89 y may also play a role in preventing central nervous system diseases in HIV-positive individuals.
90  disrupted microbiome contributes to central nervous system diseases, including Alzheimer disease, Pa
91 es (ERVs) play a significant role in central nervous system diseases, including amyotrophic lateral s
92 de, which is considered to be connected with nervous system diseases, including dementia and cognitiv
93  pain and in rare cases can lead to brain or nervous system diseases, including Guillain-Barre syndro
94 ontributes to the pathogenesis of peripheral nervous system diseases, including sensory neuropathies,
95  of neuronal injury for a variety of central nervous system diseases, including stroke and neurodegen
96 A key hurdle for drug discoverers of central nervous system disease is a lack of high quality neurona
97 ignificance was the finding that the central nervous system disease is brain autonomous.
98           The effective treatment of central nervous system diseases is a major challenge due to the
99  that is effective for both types of central nervous system disease, is so toxic that it kills 5% of
100 (MOG) are associated with autoimmune central nervous system diseases like acute disseminated encephal
101  characterized as an immune-mediated central nervous system disease marked by chronic inflammation, d
102  complex diseases such as cancer and central nervous system diseases may require complex therapeutic
103 eased concentrations in inflammatory central nervous system diseases, may profoundly affect microglia
104 E) is an animal model for autoimmune central nervous system disease mediated by CD4 T cells.
105 s is an inflammatory, demyelinating, central nervous system disease mediated by myelin-specific T cel
106                   In comparison to mammalian nervous system disease models, the zebrafish allows test
107 tis (EAE) is an animal model for the central nervous system disease multiple sclerosis (MS).
108 le neurological decline in the human central nervous system disease, multiple sclerosis (MS).
109 vestigation included cancer (n = 31; 23.1%), nervous system diseases (n = 26; 19.4%), and injury and
110                                          The Nervous System Disease NcRNAome Atlas (NSDNA) is a manua
111  of the most complex biological systems, and nervous system disease (NSD) is a major cause of disabil
112  experimentally supported associations about nervous system diseases (NSDs) and noncoding RNAs (ncRNA
113 ant oligoclonal IgGs in inflammatory central nervous system diseases of unknown cause.
114 to what exactly defines biologically central nervous system disease or what specific cerebrospinal fl
115 uch as renal disease (P < 0.0001) or central nervous system disease (P < 0.0025).
116 rtension, pulmonary dysfunction, and central nervous system disease persisted, following treatment.
117      Death was associated with acute central nervous system disease, prolonged ventilation, treatment
118 emarkably similar to humans with sympathetic nervous system disease, raising the possibility that it
119 , chronic obstructive pulmonary disease, and nervous system disease relative to comparable US women.
120 y and neurodegenerative pathology in central nervous system diseases such as epilepsy, Alzheimer's di
121 reutzfeldt-Jakob's disease and other central nervous system diseases such as Parkinson's and Huntingt
122  been differentially associated with central nervous system diseases, suggesting an HHV-6 variant-spe
123 tible to both neuronal infection and central nervous system disease than their immunocompetent litter
124 gher rate of disease progression and central nervous system disease than those infected with HIV-1 al
125 derlying basis of the characteristic central nervous system disease that occurs following intracerebr
126 patients with clinically distinctive central nervous system diseases that appear to benefit from immu
127 he most recent published findings of central nervous system diseases that have evidence of a post-str
128 ipah virus (NiV), which cause lethal central nervous system diseases-the addition of cholesterol to a
129 lso had more frequent renal disease, central nervous system disease, thrombocytopenia, and clotting e
130 m of diseases in humans ranging from central nervous system disease to lethal hemorrhagic fevers with
131 for therapeutic applications, especially for nervous system disease, using successive application of
132 odel of human immunodeficiency virus central nervous system disease was developed in which more than
133                                      Central nervous system disease was present at diagnosis in 13 pa
134 hic factor for the treatment of many central nervous system diseases, was delivered by IN followed by
135 y the pathogenesis of HIV-induced peripheral nervous system disease, we established a model in which
136 m respiratory, infectious and parasitic, and nervous system diseases were the outcomes.
137                    Most LSDs exhibit central nervous system disease, which is a primary contributor t
138 sit will extend the ability to model central nervous system disease while facilitating high-throughpu
139 ology will yield important insights into how nervous system diseases with systemic comorbidities aris

 
Page Top